1 3205 143 HDAC8, A POTENTIAL THERAPEUTIC TARGET, REGULATES PROLIFERATION AND DIFFERENTIATION OF BONE MARROW STROMAL CELLS IN FIBROUS DYSPLASIA. FIBROUS DYSPLASIA (FD) IS A DISEASE OF POSTNATAL SKELETAL STEM CELLS CAUSED BY ACTIVATING MUTATIONS OF GUANINE NUCLEOTIDE-BINDING PROTEIN ALPHA-STIMULATING ACTIVITY POLYPEPTIDE (GNAS). FD IS CHARACTERIZED BY HIGH PROLIFERATION AND OSTEOGENESIS DISORDER OF BONE MARROW STROMAL CELLS (BMSCS), RESULTING IN BONE PAIN, DEFORMITIES, AND FRACTURES. THE CAMP-CREB PATHWAY, WHICH IS ACTIVATED BY GNAS MUTATIONS, IS KNOWN TO BE CLOSELY ASSOCIATED WITH THE OCCURRENCE OF FD. HOWEVER, SO FAR THERE IS NO AVAILABLE TARGETED THERAPEUTIC STRATEGY FOR FD, AS A CRITICAL ISSUE THAT REMAINS LARGELY UNKNOWN IS HOW THIS PATHWAY IS INVOLVED IN FD. OUR PREVIOUS STUDY REVEALED THAT HISTONE DEACETYLASE 8 (HDAC8) INHIBITED THE OSTEOGENIC DIFFERENTIATION OF BMSCS VIA EPIGENETIC REGULATION. HERE, COMPARED WITH NORMAL BMSCS, FD BMSCS EXHIBITED SIGNIFICANTLY HIGH PROLIFERATION AND WEAK OSTEOGENIC CAPACITY IN RESPONSE TO HDAC8 UPREGULATION AND TUMOR PROTEIN 53 (TP53) DOWNREGULATION. MOREOVER, INHIBITION OF CAMP REDUCED HDAC8 EXPRESSION, INCREASED TP53 EXPRESSION AND RESULTED IN THE IMPROVEMENT OF FD PHENOTYPE. IMPORTANTLY, HDAC8 INHIBITION PREVENTED CAMP-INDUCED CELL PHENOTYPE AND PROMOTED OSTEOGENESIS IN NUDE MICE THAT WERE IMPLANTED WITH FD BMSCS. MECHANISTICALLY, HDAC8 WAS IDENTIFIED AS A TRANSCRIPTIONAL TARGET GENE OF CREB1 AND ITS TRANSCRIPTION WAS DIRECTLY ACTIVATED BY CREB1 IN FD BMSCS. IN SUMMARY, OUR STUDY REVEALS THAT HDAC8 ASSOCIATES WITH FD PHENOTYPE AND DEMONSTRATES THE MECHANISMS REGULATED BY CAMP-CREB1-HDAC8 PATHWAY. THESE RESULTS PROVIDE INSIGHTS INTO THE MOLECULAR REGULATION OF FD PATHOGENESIS, AND OFFER NOVEL CLUES THAT SMALL MOLECULE INHIBITORS TARGETING HDAC8 ARE PROMISING CLINICAL TREATMENT FOR FD. STEM CELLS TRANSLATIONAL MEDICINE 2019;8:148&14. 2019 2 1999 24 EPIGENETIC AND NEURONAL ACTIVITY MARKERS SUGGEST THE RECRUITMENT OF THE PREFRONTAL CORTEX AND HIPPOCAMPUS IN THE THREE-HIT MODEL OF DEPRESSION IN MALE PACAP HETEROZYGOUS MICE. DEPRESSION AND ITS INCREASING PREVALENCE CHALLENGE PATIENTS, THE HEALTHCARE SYSTEM, AND THE ECONOMY. WE RECENTLY CREATED A MOUSE MODEL BASED ON THE THREE-HIT CONCEPT OF DEPRESSION. AS GENETIC PREDISPOSITION (FIRST HIT), WE APPLIED PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE HETEROZYGOUS MICE ON CD1 BACKGROUND. MATERNAL DEPRIVATION MODELED THE EPIGENETIC FACTOR (SECOND HIT), AND THE CHRONIC VARIABLE MILD STRESS WAS THE ENVIRONMENTAL FACTOR (THIRD HIT). FLUOXETINE TREATMENT WAS APPLIED TO TEST THE PREDICTIVE VALIDITY OF OUR MODEL. WE AIMED TO EXAMINE THE DYNAMICS OF THE EPIGENETIC MARKER ACETYL-LYSINE 9 H3 HISTONE (H3K9AC) AND THE NEURONAL ACTIVITY MARKER FOSB IN THE PREFRONTAL CORTEX (PFC) AND HIPPOCAMPUS. FLUOXETINE DECREASED H3K9AC IN PFC IN NON-DEPRIVED ANIMALS, BUT A HISTORY OF MATERNAL DEPRIVATION ABOLISHED THE EFFECT OF STRESS AND SSRI TREATMENT ON H3K9AC IMMUNOREACTIVITY. IN THE HIPPOCAMPUS, STRESS DECREASED, WHILE SSRI INCREASED H3K9AC IMMUNOSIGNAL, UNLIKE IN THE DEPRIVED MICE, WHERE THE OPPOSITE EFFECT WAS DETECTED. FOSB IN STRESS WAS STIMULATED BY FLUOXETINE IN THE PFC, WHILE IT WAS INHIBITED IN THE HIPPOCAMPUS. THE FOSB IMMUNOREACTIVITY WAS ALMOST COMPLETELY ABOLISHED IN THE HIPPOCAMPUS OF THE DEPRIVED MICE. THIS STUDY SHOWED THAT FOSB AND H3K9AC WERE MODULATED IN A TERRITORY-SPECIFIC MANNER BY EARLY LIFE ADVERSITIES AND LATER LIFE STRESS INTERACTING WITH THE EFFECT OF FLUOXETINE THERAPY SUPPORTING THE RELIABILITY OF OUR MODEL. 2022 3 5715 45 SIRT3 RESTRICTS HEPATITIS B VIRUS TRANSCRIPTION AND REPLICATION THROUGH EPIGENETIC REGULATION OF COVALENTLY CLOSED CIRCULAR DNA INVOLVING SUPPRESSOR OF VARIEGATION 3-9 HOMOLOG 1 AND SET DOMAIN CONTAINING 1A HISTONE METHYLTRANSFERASES. HEPATITIS B VIRUS (HBV) INFECTION REMAINS A MAJOR HEALTH PROBLEM WORLDWIDE. MAINTENANCE OF THE COVALENTLY CLOSED CIRCULAR DNA (CCCDNA), WHICH SERVES AS A TEMPLATE FOR HBV RNA TRANSCRIPTION, IS RESPONSIBLE FOR THE FAILURE OF ERADICATING CHRONIC HBV DURING CURRENT ANTIVIRAL THERAPY. CCCDNA IS ASSEMBLED WITH CELLULAR HISTONE PROTEINS INTO CHROMATIN, BUT LITTLE IS KNOWN ABOUT THE REGULATION OF HBV CHROMATIN BY HISTONE POSTTRANSLATIONAL MODIFICATIONS. IN THIS STUDY, WE IDENTIFIED SILENT MATING TYPE INFORMATION REGULATION 2 HOMOLOG 3 (SIRT3) AS A HOST FACTOR RESTRICTING HBV TRANSCRIPTION AND REPLICATION BY SCREENING SEVEN MEMBERS OF THE SIRTUIN FAMILY, WHICH IS THE CLASS III HISTONE DEACETYLASE. ECTOPIC SIRT3 EXPRESSION SIGNIFICANTLY REDUCED TOTAL HBV RNAS, 3.5-KB RNA, AS WELL AS REPLICATIVE INTERMEDIATE DNA IN HBV-INFECTED HEPG2-NA(+) /TAUROCHOLATE COTRANSPORTING POLYPEPTIDE CELLS AND PRIMARY HUMAN HEPATOCYTES. IN CONTRAST, GENE SILENCING OF SIRT3 PROMOTED HBV TRANSCRIPTION AND REPLICATION. A MECHANISTIC STUDY FOUND THAT NUCLEAR SIRT3 WAS RECRUITED TO THE HBV CCCDNA, WHERE IT DEACETYLATED HISTONE 3 LYSINE 9. IMPORTANTLY, OCCUPANCY OF SIRT3 ON CCCDNA COULD INCREASE THE RECRUITMENT OF HISTONE METHYLTRANSFERASE SUPPRESSOR OF VARIEGATION 3-9 HOMOLOG 1 TO CCCDNA AND DECREASE RECRUITMENT OF SET DOMAIN CONTAINING 1A, LEADING TO A MARKED INCREASE OF TRIMETHYL-HISTONE H3 (LYS9) AND A DECREASE OF TRIMETHYL-HISTONE H3 (LYS4) ON CCCDNA. MOREOVER, SIRT3-MEDIATED HBV CCCDNA TRANSCRIPTIONAL REPRESSION INVOLVED DECREASED BINDING OF HOST RNA POLYMERASE II AND TRANSCRIPTION FACTOR YIN YANG 1 TO CCCDNA. FINALLY, HEPATITIS B VIRAL X PROTEIN COULD RELIEVE SIRT3-MEDIATED CCCDNA TRANSCRIPTIONAL REPRESSION BY INHIBITING BOTH SIRT3 EXPRESSION AND ITS RECRUITMENT TO CCCDNA. CONCLUSION: SIRT3 IS A HOST FACTOR EPIGENETICALLY RESTRICTING HBV CCCDNA TRANSCRIPTION BY ACTING COOPERATIVELY WITH HISTONE METHYLTRANSFERASE; THESE DATA PROVIDE A RATIONALE FOR THE USE OF SIRT3 ACTIVATORS IN THE PREVENTION OR TREATMENT OF HBV INFECTION. (HEPATOLOGY 2018). 2018 4 1637 31 DOES DYSREGULATION OF KEY EPIGENETIC AND BIOCHEMICAL PATHWAYS OCCUR IN POSTULATED VASOACTIVE NEUROPEPTIDE AUTOIMMUNE DISORDERS? AUTOIMMUNE DYSFUNCTION OF CERTAIN VASOACTIVE NEUROPEPTIDES (VNS) HAS BEEN POSTULATED AS A CONTRIBUTING CAUSE OF SUDDEN INFANT DEATH SYNDROME (SIDS), CHRONIC FATIGUE SYNDROME (CFS), GULF WAR SYNDROME (GWS) AND OTHER FATIGUE-RELATED DISORDERS. THIS FAMILY OF VNS INCLUDES PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE (PACAP), VASOACTIVE INTESTINAL PEPTIDE (VIP) AND CALCITONIN GENE RELATED PEPTIDE (CGRP). THE POSTULATED MECHANISM IS COMPROMISE OF ADENYLATE CYCLASE ACTIVATION, A VITAL AND UNIQUE STEP IN CYCLIC AMP PRODUCTION FROM ATP, THROUGH AUTOIMMUNE DYSFUNCTION OF VNS, THEIR RECEPTORS OR THEIR GENES POSSIBLY INVOLVING CYTOSINE-PHOSPHATE-GUANINE (CPG) FRAGMENTS. CPG FRAGMENTS ARE IMMUNOMODULATORY DINUCLEOTIDES SERVING AS 'FRIEND OR FOE' RECOGNITION SYSTEMS TO DIFFERENTIATE BACTERIAL AND VIRAL (HYPOMETHYLATED CPG) FROM MAMMALIAN (METHYLATED CPG) DNA. HOWEVER HYPOMETHYLATION DISORDERS AFFECTING THESE FRAGMENTS IN MAMMALS MAY CONVERT THEM TO DYSFUNCTIONAL STATES BY PROMOTING AUTOIMMUNE INFLAMMATORY REACTIONS. EPIGENETIC MECHANISMS ACTING ON GENE PROMOTER REGIONS MAY CONTRIBUTE TO THE DEVELOPMENT OF VN AUTOIMMUNE FATIGUE-RELATED DISORDERS THROUGH CPG FRAGMENTS LOCATED IN VITAL SEGMENTS OF VN/RECEPTOR GENES BY CAUSING SIGNALLING DEFECTS WITH PROFOUND IMPLICATIONS FOR VN FUNCTION. NEUROTRANSMITTER DYSFUNCTION PARTICULARLY GLUTAMATERGIC TRANSMISSION COULD ALSO RESULT WITH DISRUPTION OF NEURONAL CELLULAR BIOCHEMICAL FUNCTIONS SUCH AS AMMONIA REGULATION. ENDOSOMAL ACIDITY AND MITOCHONDRIAL MEMBRANE POTENTIAL MODIFIERS SUCH AS CHLOROQUINE, TOGETHER WITH IMMUNOREGULATORY THERAPIES, MAY HAVE THERAPEUTIC IMPLICATIONS IN PROTECTING AGAINST THESE APPARENT AUTOIMMUNE DISORDERS. THIS PAPER EXAMINES SPECIFIC EPIGENETIC AND BIOCHEMICAL MECHANISMS POSSIBLY MEDIATED BY VN OR RECEPTOR GENES RESULTING IN POSTULATED VN AUTOIMMUNE FATIGUE-RELATED DISORDERS. THESE MECHANISMS MAY HAVE IMPLICATIONS FOR TREATMENT AND PREVENTION OPTIONS FOR VN AUTOIMMUNE DISORDERS. VN AUTOIMMUNE PROCESSES HAVE IMPLICATIONS FOR MILITARY MEDICINE WHERE RADIOLOGICAL, CHEMICAL AND BIOLOGICAL AGENTS MAY PLAY AN IMPORTANT ROLE IN PATHOGENESIS. 2005 5 2828 27 FLUOXETINE TREATMENT SUPPORTS PREDICTIVE VALIDITY OF THE THREE HIT MODEL OF DEPRESSION IN MALE PACAP HETEROZYGOUS MICE AND UNDERPINS THE IMPACT OF EARLY LIFE ADVERSITY ON THERAPEUTIC EFFICACY. ACCORDING TO THE THREE HIT CONCEPT OF DEPRESSION, INTERACTION OF GENETIC PREDISPOSITION ALTERED EPIGENETIC PROGRAMMING AND ENVIRONMENTAL STRESS FACTORS CONTRIBUTE TO THE DISEASE. EARLIER WE DEMONSTRATED THE CONSTRUCT AND FACE VALIDITY OF OUR THREE HIT CONCEPT-BASED MOUSE MODEL. IN THE PRESENT WORK, WE AIMED TO EXAMINE THE PREDICTIVE VALIDITY OF OUR MODEL, THE THIRD WILLNERIAN CRITERION. FLUOXETINE TREATMENT WAS APPLIED IN CHRONIC VARIABLE MILD STRESS (CVMS)-EXPOSED (ENVIRONMENTAL HIT) CD1 MICE CARRYING ONE MUTATED ALLELE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE GENE (GENETIC HIT) THAT WERE PREVIOUSLY EXPOSED TO MATERNAL DEPRIVATION (EPIGENETIC HIT) VS. CONTROLS. FLUOXETINE REDUCED THE ANXIETY LEVEL IN CVMS-EXPOSED MICE IN MARBLE BURYING TEST, AND DECREASED THE DEPRESSION LEVEL IN TAIL SUSPENSION TEST IF MICE WERE NOT DEPRIVED MATERNALLY. HISTORY OF MATERNAL DEPRIVATION CAUSED FUNDAMENTAL FUNCTIONAL-MORPHOLOGICAL CHANGES IN RESPONSE TO CVMS AND FLUOXETINE TREATMENT IN THE CORTICOTROPIN-RELEASING HORMONE-PRODUCING CELLS OF THE BED NUCLEUS OF THE STRIA TERMINALIS AND CENTRAL AMYGDALA, IN TYROSINE-HYDROXYLASE CONTENT OF VENTRAL TEGMENTAL AREA, IN UROCORTIN 1-EXPRESSING CELLS OF THE CENTRALLY PROJECTING EDINGER-WESTPHAL NUCLEUS, AND SEROTONERGIC CELLS OF THE DORSAL RAPHE NUCLEUS. THE EPIGENETIC BACKGROUND OF ALTERATIONS WAS APPROVED BY ALTERED ACETYLATION OF HISTONE H3. OUR FINDINGS FURTHER SUPPORT THE VALIDITY OF BOTH THE THREE HIT CONCEPT AND THAT OF OUR ANIMAL MODEL. REVERSAL OF BEHAVIORAL AND FUNCTIONAL-MORPHOLOGICAL ANOMALIES BY FLUOXETINE TREATMENT SUPPORTS THE PREDICTIVE VALIDITY OF THE MODEL. THIS STUDY HIGHLIGHTS THAT EARLY LIFE STRESS DOES NOT ONLY INTERACT WITH THE GENETIC AND ENVIRONMENTAL FACTORS, BUT HAS STRONG INFLUENCE ALSO ON THERAPEUTIC EFFICACY. 2022 6 310 36 ALCOHOL AND NMDA RECEPTOR: CURRENT RESEARCH AND FUTURE DIRECTION. THE BRAIN IS ONE OF THE MAJOR TARGETS OF ALCOHOL ACTIONS. MOST OF THE EXCITATORY SYNAPTIC TRANSMISSION IN THE CENTRAL NERVOUS SYSTEM IS MEDIATED BY N-METHYL-D-ASPARTATE (NMDA) RECEPTORS. HOWEVER, ONE OF THE MOST DEVASTATING EFFECTS OF ALCOHOL LEADS TO BRAIN SHRINKAGE, LOSS OF NERVE CELLS AT SPECIFIC REGIONS THROUGH A MECHANISM INVOLVING EXCITOTOXICITY, OXIDATIVE STRESS. EARLIER STUDIES HAVE INDICATED THAT CHRONIC EXPOSURE TO ETHANOL BOTH IN VIVO AND IN VITRO, INCREASES NR1 AND NR2B GENE EXPRESSION AND THEIR POLYPEPTIDE LEVELS. THE EFFECT OF ALCOHOL AND MOLECULAR CHANGES ON THE REGULATORY PROCESS, WHICH MODULATES NMDAR FUNCTIONS INCLUDING FACTORS ALTERING TRANSCRIPTION, TRANSLATION, POST-TRANSLATIONAL MODIFICATIONS, AND PROTEIN EXPRESSION, AS WELL AS THOSE INFLUENCING THEIR INTERACTIONS WITH DIFFERENT REGULATORY PROTEINS (DOWNSTREAM EFFECTORS) ARE INCESSANTLY INCREASING AT THE CELLULAR LEVEL. FURTHER, I DISCUSS THE VARIOUS GENETICALLY ALTERED MICE APPROACHES THAT HAVE BEEN USED TO STUDY NMDA RECEPTOR SUBUNITS AND THEIR FUNCTIONAL IMPLICATION. IN A RECENT COUNTABLE REVIEW, EPIGENETIC DIMENSION (I.E., HISTONE MODIFICATION-INDUCED CHROMATIN REMODELING AND DNA METHYLATION, IN THE PROCESS OF ALCOHOL RELATED NEUROADAPTATION) IS ONE OF THE KEY MOLECULAR MECHANISMS IN ALCOHOL MEDIATED NMDAR ALTERATION. HERE, I PROVIDE A RECOUNT ON WHAT HAS ALREADY BEEN ACHIEVED, CURRENT TRENDS AND HOW THE FUTURE RESEARCH/STUDIES OF THE NMDA RECEPTOR MIGHT LEAD TO EVEN GREATER ENGAGEMENT WITH MANY POSSIBLE NEW INSIGHTS INTO THE NEUROBIOLOGY AND TREATMENT OF ALCOHOLISM. 2013 7 4239 33 METHYLATION PROFILE OF HEPATITIS B VIRUS IS NOT INFLUENCED BY INTERFERON ALPHA IN HUMAN LIVER CANCER CELLS. INTERFERON (IFN) ALPHA IS USED FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION, BUT THE MOLECULAR MECHANISMS UNDERLYING ITS ANTIVIRAL EFFECT HAVE NOT BEEN FULLY ELUCIDATED. EPIGENETIC MODIFICATIONS REGULATE THE TRANSCRIPTIONAL ACTIVITY OF COVALENTLY CLOSED CIRCULAR DNA (CCCDNA) IN CELLS WITH CHRONIC HBV INFECTION. IFN?ALPHA HAS BEEN SHOWN TO MODIFY CCCDNA?BOUND HISTONES, BUT IT IS NOT KNOWN WHETHER THE ANTI?HBV EFFECT OF IFN?ALPHA INVOLVES METHYLATION OF CCCDNA. THE PRESENT STUDY AIMED TO DETERMINE WHETHER IFN?ALPHA INDUCED METHYLATION OF HBV CCCDNA IN A CELL?BASED MODEL IN WHICH HEPG2 CELLS WERE DIRECTLY INFECTED WITH WILD?TYPE HBV VIRIONS. METHYLATION STATUS OF HBV CCCDNA WAS ASSESSED USING GLOBAL DNA METHYLATION ELISA ASSAY, METHYLATION?SPECIFIC PCR AND BISULFITE SEQUENCING. IFN?ALPHA SUPPRESSED HBV DNA AND RNA TRANSCRIPTS, BUT METHYLATION PROFILES WERE SIMILAR BETWEEN THE CONTROL AND IFN?ALPHA TREATED GROUPS. CHROMATIN IMMUNOPRECIPITATION RESULTS REVEALED BINDING OF DNA METHYLTRANSFERASES (DNMT) 3A AND DNMT3B TO HBV CCCDNA AND TREATMENT WITH IFN?ALPHA SUPPRESSED THE RECRUITMENT OF DNMT3B TO CCCDNA. TAKEN TOGETHER, THESE RESULTS SUGGEST THAT IFN?ALPHA DOES NOT INDUCE METHYLATION OF HBV CCCDNA. THEREFORE, IT WAS CONCLUDED THAT METHYLATION IS UNLIKELY TO CONTRIBUTE TO THE ANTI?HBV EFFECT OF IFN?ALPHA IN HEPG2 CELLS, AND THAT ALTERNATIVE MECHANISMS NEED TO BE SOUGHT TO ENHANCE CCCDNA METHYLATION AS A NOVEL THERAPY AGAINST HBV. 2021 8 5226 39 PRMT5 RESTRICTS HEPATITIS B VIRUS REPLICATION THROUGH EPIGENETIC REPRESSION OF COVALENTLY CLOSED CIRCULAR DNA TRANSCRIPTION AND INTERFERENCE WITH PREGENOMIC RNA ENCAPSIDATION. CHRONIC HEPATITIS B VIRUS (HBV) INFECTION REMAINS A MAJOR HEALTH PROBLEM WORLDWIDE. THE COVALENTLY CLOSED CIRCULAR DNA (CCCDNA) MINICHROMOSOME, WHICH SERVES AS THE TEMPLATE FOR THE TRANSCRIPTION OF VIRAL RNAS, PLAYS A KEY ROLE IN VIRAL PERSISTENCE. WHILE ACCUMULATING EVIDENCE SUGGESTS THAT CCCDNA TRANSCRIPTION IS REGULATED BY EPIGENETIC MACHINERY, PARTICULARLY THE ACETYLATION OF CCCDNA-BOUND HISTONE 3 (H3) AND H4, THE POTENTIAL CONTRIBUTIONS OF HISTONE METHYLATION AND RELATED HOST FACTORS REMAIN OBSCURE. HERE, BY SCREENING A SERIES OF METHYLTRANSFERASES AND DEMETHYLASES, WE IDENTIFIED PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) AS AN EFFECTIVE RESTRICTOR OF HBV TRANSCRIPTION AND REPLICATION. IN CELL CULTURE-BASED MODELS FOR HBV INFECTION AND IN LIVER TISSUES OF PATIENTS WITH CHRONIC HBV INFECTION, WE FOUND THAT SYMMETRIC DIMETHYLATION OF ARGININE 3 ON H4 ON CCCDNA WAS A REPRESSIVE MARKER OF CCCDNA TRANSCRIPTION AND WAS REGULATED BY PRMT5 DEPENDING ON ITS METHYLTRANSFERASE DOMAIN. MOREOVER, PRMT5-TRIGGERED SYMMETRIC DIMETHYLATION OF ARGININE 3 ON H4 ON THE CCCDNA MINICHROMOSOME INVOLVED AN INTERACTION WITH THE HBV CORE PROTEIN AND THE BRG1-BASED HUMAN SWI/SNF CHROMATIN REMODELER, WHICH RESULTED IN DOWN-REGULATION OF THE BINDING OF RNA POLYMERASE II TO CCCDNA. IN ADDITION TO THE INHIBITORY EFFECT ON CCCDNA TRANSCRIPTION, PRMT5 INHIBITED HBV CORE PARTICLE DNA PRODUCTION INDEPENDENTLY OF ITS METHYLTRANSFERASE ACTIVITY. FURTHER STUDY REVEALED THAT PRMT5 INTERFERED WITH PREGENOMIC RNA ENCAPSIDATION BY PREVENTING ITS INTERACTION WITH VIRAL POLYMERASE PROTEIN THROUGH BINDING TO THE REVERSE TRANSCRIPTASE-RIBONUCLEASE H REGION OF POLYMERASE, WHICH IS CRUCIAL FOR THE POLYMERASE-PREGENOMIC RNA INTERACTION. CONCLUSION: PRMT5 RESTRICTS HBV REPLICATION THROUGH A TWO-PART MECHANISM INCLUDING EPIGENETIC SUPPRESSION OF CCCDNA TRANSCRIPTION AND INTERFERENCE WITH PREGENOMIC RNA ENCAPSIDATION; THESE FINDINGS IMPROVE THE UNDERSTANDING OF EPIGENETIC REGULATION OF HBV TRANSCRIPTION AND HOST-HBV INTERACTION, THUS PROVIDING NEW INSIGHTS INTO TARGETED THERAPEUTIC INTERVENTION. (HEPATOLOGY 2017;66:398-415). 2017 9 4055 34 MAPPING OF HISTONE MODIFICATIONS IN EPISOMAL HBV CCCDNA UNCOVERS AN UNUSUAL CHROMATIN ORGANIZATION AMENABLE TO EPIGENETIC MANIPULATION. CHRONIC HEPATITIS B VIRUS (HBV) INFECTION AFFECTS 240 MILLION PEOPLE WORLDWIDE AND IS A MAJOR RISK FACTOR FOR LIVER FAILURE AND HEPATOCELLULAR CARCINOMA. CURRENT ANTIVIRAL THERAPY INHIBITS CYTOPLASMIC HBV GENOMIC REPLICATION, BUT IS NOT CURATIVE BECAUSE IT DOES NOT DIRECTLY AFFECT NUCLEAR HBV CLOSED CIRCULAR DNA (CCCDNA), THE GENOMIC FORM THAT TEMPLATES VIRAL TRANSCRIPTION AND SUSTAINS VIRAL PERSISTENCE. NOVEL APPROACHES THAT DIRECTLY TARGET CCCDNA REGULATION WOULD THEREFORE BE HIGHLY DESIRABLE. CCCDNA IS ASSEMBLED WITH CELLULAR HISTONE PROTEINS INTO CHROMATIN, BUT LITTLE IS KNOWN ABOUT THE REGULATION OF HBV CHROMATIN BY HISTONE POSTTRANSLATIONAL MODIFICATIONS (PTMS). HERE, USING A NEW CCCDNA CHIP-SEQ APPROACH, WE REPORT, TO OUR KNOWLEDGE, THE FIRST GENOME-WIDE MAPS OF PTMS IN CCCDNA-CONTAINING CHROMATIN FROM DE NOVO INFECTED HEPG2 CELLS, PRIMARY HUMAN HEPATOCYTES, AND FROM HBV-INFECTED LIVER TISSUE. WE FIND HIGH LEVELS OF PTMS ASSOCIATED WITH ACTIVE TRANSCRIPTION ENRICHED AT SPECIFIC SITES WITHIN THE HBV GENOME AND, SURPRISINGLY, VERY LOW LEVELS OF PTMS LINKED TO TRANSCRIPTIONAL REPRESSION EVEN AT SILENT HBV PROMOTERS. WE SHOW THAT TRANSCRIPTION AND ACTIVE PTMS IN HBV CHROMATIN ARE REDUCED BY THE ACTIVATION OF AN INNATE IMMUNITY PATHWAY, AND THAT THIS EFFECT CAN BE RECAPITULATED WITH A SMALL MOLECULE EPIGENETIC MODIFYING AGENT, OPENING THE POSSIBILITY THAT CHROMATIN-BASED REGULATION OF CCCDNA TRANSCRIPTION COULD BE A NEW THERAPEUTIC APPROACH TO CHRONIC HBV INFECTION. 2015 10 2401 39 EPIGENETIC REPROGRAMMING PROMOTES THE ANTIVIRAL ACTION OF IFNALPHA IN HBV-INFECTED CELLS. CHRONIC HEPATITIS B VIRUS (HBV) INFECTIONS REMAIN A HEALTH BURDEN AFFECTING ~250 MILLION PEOPLE WORLDWIDE. THUS FAR, AVAILABLE INTERFERON-ALPHA (IFNALPHA)-BASED THERAPIES HAVE SHOWN UNSATISFACTORY CURE RATES, AND ALTERNATIVE THERAPEUTIC MOLECULES ARE STILL REQUIRED. HOWEVER, THEIR DEVELOPMENT HAS BEEN HAMPERED BECAUSE ACCESSIBLE CELL MODELS SUPPORTING RELEVANT HBV REPLICATION AND APPROPRIATE ANTIVIRAL ACTIVITY ARE LACKING. STRATEGIES THAT REVERSE EPIGENETIC ALTERATIONS OFFER A UNIQUE OPPORTUNITY FOR CELL REPROGRAMMING, WHICH IS VALUABLE FOR RESTORING ALTERED CELLULAR FUNCTIONS IN HUMAN CELL LINES. THIS WORK AIMED TO INVESTIGATE THE FEASIBILITY OF CONVERTING HEPG2 CELLS THAT STABLY OVEREXPRESS THE HBV ENTRY RECEPTOR (SODIUM/TAUROCHOLATE COTRANSPORTING POLYPEPTIDE, NTCP) TOWARD IFNALPHA-RESPONSIVE CELLS USING EPIGENETIC REPROGRAMMING. HEREIN, WE SHOWED THAT AN EPIGENETIC REGIMEN WITH NON-CYTOTOXIC DOSES OF THE DEMETHYLATING COMPOUND 5-AZACYTIDINE RESTORED THE ANTI-HBV ACTION OF IFNALPHA IN EPIGENETICALLY REPROGRAMMED HEPG2-NTCP-C4 CELLS, NAMED REP-HEPG2-NTCP CELLS. THUS, A SIGNIFICANT INHIBITION IN HBV DNA LEVELS WAS MEASURED IN REP-HEPG2-NTCP CELLS AFTER IFNALPHA TREATMENT. THIS INHIBITORY EFFECT WAS ASSOCIATED WITH THE ENHANCEMENT OF IFNALPHA-MEDIATED INDUCTION OF CRITICAL INTERFERON-STIMULATED GENES (ISGS), WHICH WAS LIMITED IN NON-REPROGRAMMED CELLS. IN PARTICULAR, OUR DATA INDICATED THAT RE-EXPRESSION OF 2'-5'-OLIGOADENYLATE SYNTHETASE 1 (OAS1) AND INTERFERON REGULATORY FACTOR 9 (IRF9) WAS THE RESULT OF AN EPIGENETICALLY DRIVEN UNMASKING OF THESE GENES IN REPROGRAMMED CELLS. AT LAST, WE EVALUATED THE THERAPEUTIC POTENTIAL OF THE IFN ANALOG CDM-3008 IN REP-HEPG2-NTCP CELLS AND DEMONSTRATED THE EFFICIENCY OF THIS CHEMICAL COMPOUND IN TRIGGERING ISG INDUCTION AND HBV INHIBITION. IN SUMMARY, THIS STUDY SHOWS THAT EPIGENETIC REPROGRAMMING PROMOTES THE IFNALPHA RESPONSE IN HBV-INFECTED CELLS AND IS POTENTIALLY ATTRACTIVE FOR CELL-BASED EXPERIMENTAL SCREENING OF IFN-LIKE COMPOUNDS. 2021 11 4357 38 MIR-30E* IS OVEREXPRESSED IN PROSTATE CANCER AND PROMOTES NF-KAPPAB-MEDIATED PROLIFERATION AND TUMOR GROWTH. ACCORDING TO THE CDC PROSTATE CANCER (CAP) HAS THE HIGHEST INCIDENCE AND SECOND HIGHEST MORTALITY RATE AMONGST CANCERS IN AMERICAN MEN. CONSTITUTIVE NF-KAPPAB ACTIVATION IS A HALLMARK OF CAP AND THIS PATHWAY DRIVES MANY PRO-TUMORIGENIC CHARACTERISTICS OF CAP CELLS, INCLUDING CELL PROLIFERATION AND SURVIVAL. AN ACTIVATED NF-KAPPAB GENE SIGNATURE IS PREDICTIVE OF CAP PROGRESSION AND BIOCHEMICAL RECURRENCE FOLLOWING THERAPEUTIC INTERVENTION. HOWEVER, THE MECHANISMS THAT PERPETUATE NF-KAPPAB ACTIVATION ARE INCOMPLETELY UNDERSTOOD. GENES THAT CONTROL NF-KAPPAB ACTIVITY ARE RARELY MUTATED IN CAP SUGGESTING THAT EPIGENETIC MECHANISMS MAY CONTRIBUTE TO CONSTITUTIVE NF-KAPPAB ACTIVATION. MICRORNAS (MIRS) EPIGENETICALLY REGULATE MANY GENES INVOLVED WITH NF-KAPPAB ACTIVATION. IKAPPABALPHA IS A DIRECT INHIBITOR OF NF-KAPPAB; IT BINDS TO AND SEQUESTERS NF-KAPPAB IN THE CYTOPLASM RESULTING IN FUNCTIONAL INHIBITION. IKAPPABALPHA IS A TARGET GENE OF MIR-30E* YET THE EXPRESSION AND ONCOLOGICAL IMPACT OF MIR-30E* IN CAP IS UNKNOWN. WE REPORT THAT MIR-30E* EXPRESSION IS ELEVATED IN MULTIPLE MURINE MODELS OF CAP AND IS MOST PRONOUNCED IN LATE STAGE DISEASE. MIR-30E* DRIVES CAP PROLIFERATION AND TUMOR GROWTH THROUGH INHIBITION OF IKAPPABALPHA, WHICH RESULTS IN CHRONIC ACTIVATION OF NF-KAPPAB. ADDITIONALLY, WE SHOW THAT INHIBITION OF MIR-30E* IMPROVES CHEMOTHERAPEUTIC CONTROL OF CAP. THUS, MIR-30E* MAY PROVE TO BE A NOVEL CLINICAL TARGET WHOSE INHIBITION LEADS TO DECREASED CAP CELL PROLIFERATION AND SENSITIZATION OF CAP CELLS TO CHEMOTHERAPEUTICS. 2017 12 329 34 ALPHA-OXOGLUTARATE INHIBITS THE PROLIFERATION OF IMMORTALIZED NORMAL BLADDER EPITHELIAL CELLS VIA AN EPIGENETIC SWITCH INVOLVING ARID1A. INTERSTITIAL CYSTITIS (IC) IS A CHRONIC URINARY TRACT DISEASE THAT IS CHARACTERIZED BY UNPLEASANT SENSATIONS, SUCH AS PERSISTENT PELVIC PAIN, IN THE ABSENCE OF INFECTION OR OTHER IDENTIFIABLE CAUSES. WE PREVIOUSLY PERFORMED COMPREHENSIVE METABOLOMICS PROFILING OF URINE SAMPLES FROM IC PATIENTS USING NUCLEAR MAGNETIC RESONANCE AND GAS-CHROMATOGRAPHY/MASS SPECTROMETRY AND FOUND THAT URINARY ALPHA-OXOGLUTARATE (ALPHA-OG), WAS SIGNIFICANTLY ELEVATED. ALPHA-OG, A TRICARBOXYLIC ACID (TCA) CYCLE INTERMEDIATE, REPORTEDLY FUNCTIONS TO SUPPRESS THE PROLIFERATION OF IMMORTALIZED NORMAL HUMAN BLADDER EPITHELIAL CELLS. HERE, WE IDENTIFIED AT-RICH INTERACTIVE DOMAIN 1 A (ARID1A), A KEY CHROMATIN REMODELER, AS BEING HYPOMETHYLATED AND UPREGULATED BY ALPHA-OG TREATMENT. THIS WAS DONE THROUGH EPIC DNA METHYLATION PROFILING AND SUBSEQUENT BIOCHEMICAL APPROACHES, INCLUDING QUANTITATIVE RT-PCR AND WESTERN BLOT ANALYSES. FURTHERMORE, WE FOUND THAT ALPHA-OG ALMOST COMPLETELY SUPPRESSES TEN-ELEVEN TRANSLOCATION (TET) ACTIVITY, BUT DOES NOT AFFECT DNA METHYLTRANSFERASE (DNMT) ACTIVITY. ALTOGETHER, OUR STUDIES REVEAL THE POTENTIAL ROLE OF ALPHA-OG IN EPIGENETIC REMODELING THROUGH ITS EFFECTS ON ARID1A AND TET EXPRESSION IN THE BLADDER. THIS MAY PROVIDE A NEW POSSIBLE THERAPEUTIC STRATEGY IN TREATING IC. 2018 13 2826 38 FLUOXETINE EPIGENETICALLY ALTERS THE CAMKIIALPHA PROMOTER IN NUCLEUS ACCUMBENS TO REGULATE DELTAFOSB BINDING AND ANTIDEPRESSANT EFFECTS. CHRONIC SOCIAL DEFEAT STRESS IN MICE PRODUCES A SUSCEPTIBLE PHENOTYPE CHARACTERIZED BY SEVERAL BEHAVIORAL ABNORMALITIES CONSISTENT WITH HUMAN DEPRESSION THAT ARE REVERSED BY CHRONIC BUT NOT ACUTE EXPOSURE TO ANTIDEPRESSANT MEDICATIONS. RECENT WORK IN ADDICTION MODELS DEMONSTRATES THAT THE TRANSCRIPTION FACTOR DELTAFOSB AND PROTEIN KINASE CALMODULIN-DEPENDENT PROTEIN KINASE II (CAMKII) ARE CO-REGULATED IN NUCLEUS ACCUMBENS (NAC), A BRAIN REWARD REGION IMPLICATED IN BOTH ADDICTION AND DEPRESSION MODELS INCLUDING SOCIAL DEFEAT. PREVIOUS WORK HAS ALSO DEMONSTRATED THAT DELTAFOSB IS INDUCED IN NAC AFTER CHRONIC SOCIAL DEFEAT STRESS OR AFTER CHRONIC ANTIDEPRESSANT TREATMENT, WHEREIN IT MEDIATES A PRO-RESILIENCE OR ANTIDEPRESSANT-LIKE PHENOTYPE. HERE, USING CHROMATIN IMMUNOPRECIPITATION ASSAYS, WE FOUND THAT DELTAFOSB BINDS THE CAMKIIALPHA GENE PROMOTER IN NAC AND THAT THIS BINDING INCREASES AFTER MICE ARE EXPOSED TO CHRONIC SOCIAL DEFEAT STRESS. PARADOXICALLY, CHRONIC EXPOSURE TO THE ANTIDEPRESSANT FLUOXETINE REDUCES BINDING OF DELTAFOSB TO THE CAMKIIALPHA PROMOTER AND REDUCES CAMKII EXPRESSION IN NAC, DESPITE THE FACT THAT DELTAFOSB IS INDUCED UNDER THESE CONDITIONS. THESE DATA SUGGEST A NOVEL EPIGENETIC MECHANISM OF ANTIDEPRESSANT ACTION, WHEREBY FLUOXETINE INDUCES SOME CHROMATIN CHANGE AT THE CAMKIIALPHA PROMOTER, WHICH BLOCKS THE DELTAFOSB BINDING. INDEED, CHRONIC FLUOXETINE REDUCES ACETYLATION AND INCREASES LYSINE-9 DIMETHYLATION OF HISTONE H3 AT THE CAMKIIALPHA PROMOTER IN NAC, EFFECTS ALSO SEEN IN DEPRESSED HUMANS EXPOSED TO ANTIDEPRESSANTS. OVEREXPRESSION OF CAMKII IN NAC BLOCKS FLUOXETINE'S ANTIDEPRESSANT EFFECTS IN THE CHRONIC SOCIAL DEFEAT PARADIGM, WHEREAS INHIBITION OF CAMKII ACTIVITY IN NAC MIMICS FLUOXETINE EXPOSURE. THESE FINDINGS SUGGEST THAT EPIGENETIC SUPPRESSION OF CAMKIIALPHA EXPRESSION IN NAC IS BEHAVIORALLY RELEVANT AND OFFER A NOVEL PATHWAY FOR POSSIBLE THERAPEUTIC INTERVENTION IN DEPRESSION AND RELATED SYNDROMES. 2014 14 6323 29 THE ROLE OF A POTENTIAL BIOMARKER IN PATIENTS WITH MIGRAINE: REVIEW AND NEW INSIGHTS. INTRODUCTION: THE SEARCH FOR AN IDEAL BIOMARKER FOR MIGRAINE HAS PERSISTED FOR A LONG TIME. THERE IS PLENTIFUL EVIDENCE OF POTENTIAL BIOMARKERS FOR MIGRAINE FOUND IN CEREBROSPINAL FLUID, BLOOD, AND SALIVA.AREAS COVERED: HEREIN, THE AUTHORS HIGHLIGHT AND DISCUSS THE MOST PROMISING CANDIDATES IN THE LITERATURE. AN ELECTRONIC SEARCH WAS PERFORMED FOR STUDIES PUBLISHED BETWEEN 2010 AND 2020 IN MEDLINE, PUBMED, AND EMBASE, RELATED TO POTENTIAL BIOMARKERS IN MIGRAINE PATIENTS, FOUND IN CEREBROSPINAL FLUID, SALIVA, AND SERUM, FOCUSING ON BIOMARKERS THAT CAN BE RELATED TO TREATMENT AND CLINICAL OUTCOMES.EXPERT OPINION: AN IDEAL BIOMARKER, OR A PANEL OF BIOMARKERS, COULD REVOLUTIONIZE THE WAY WE ADDRESS AND PROPOSE TREATMENTS FOR THIS DISEASE. ONCE SEVERE PRESENTATIONS AND PHENOTYPES HAVE BEEN IDENTIFIED USING A RELIABLE BIOMARKER, PATIENTS COULD BE TREATED AT EARLIER DISEASE STAGES WITH MORE SPECIFIC MEDICATIONS. THE MOST IMPORTANT BIOMARKERS WITH THE MOST SIGNIFICANT LEVELS OF EVIDENCE COMPRISED CALCITONIN GENE-RELATED PEPTIDE (CGRP), GLUTAMATE, NERVE GROWTH FACTOR, SOME INFLAMMATORY (CRP, TNF-ALPHA, INTERLEUKINS) AND OXIDATIVE STRESS MARKERS. CGRP WAS ASSOCIATED WITH EPISODIC, CHRONIC MIGRAINE AND RESPONSE TO TREATMENT. PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE IS AN EMERGING NEUROPEPTIDE INVOLVED IN MIGRAINE DIAGNOSTICS AND SEVERITY. NEW GENETIC AND EPIGENETIC BIOMARKERS WILL BE CANDIDATES FOR FUTURE RESEARCH. 2021 15 5716 44 SIRT6 PROTECTS VASCULAR SMOOTH MUSCLE CELLS FROM OSTEOGENIC TRANSDIFFERENTIATION VIA RUNX2 IN CHRONIC KIDNEY DISEASE. VASCULAR CALCIFICATION (VC) IS REGARDED AS AN IMPORTANT PATHOLOGICAL CHANGE LACKING EFFECTIVE TREATMENT AND ASSOCIATED WITH HIGH MORTALITY. SIRTUIN 6 (SIRT6) IS A MEMBER OF THE SIRTUIN FAMILY, A CLASS III HISTONE DEACETYLASE AND A KEY EPIGENETIC REGULATOR. SIRT6 HAS A PROTECTIVE ROLE IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD). HOWEVER, THE EXACT ROLE AND MOLECULAR MECHANISM OF SIRT6 IN VC IN PATIENTS WITH CKD REMAIN UNCLEAR. HERE, WE DEMONSTRATED THAT SIRT6 WAS MARKEDLY DOWNREGULATED IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) AND IN THE RADIAL ARTERY TISSUE OF PATIENTS WITH CKD WITH VC. SIRT6-TRANSGENIC (SIRT6-TG) MICE SHOWED ALLEVIATED VC, WHILE VASCULAR SMOOTH MUSCLE CELL-SPECIFIC (VSMC-SPECIFIC) SIRT6 KNOCKED-DOWN MICE SHOWED SEVERE VC IN CKD. SIRT6 SUPPRESSED THE OSTEOGENIC TRANSDIFFERENTIATION OF VSMCS VIA REGULATION OF RUNT-RELATED TRANSCRIPTION FACTOR 2 (RUNX2). COIMMUNOPRECIPITATION (CO-IP) AND IMMUNOPRECIPITATION (IP) ASSAYS CONFIRMED THAT SIRT6 BOUND TO RUNX2. MOREOVER, RUNX2 WAS DEACETYLATED BY SIRT6 AND FURTHER PROMOTED NUCLEAR EXPORT VIA EXPORTIN 1 (XPO1), WHICH IN TURN CAUSED DEGRADATION OF RUNX2 THROUGH THE UBIQUITIN-PROTEASOME SYSTEM. THESE RESULTS DEMONSTRATED THAT SIRT6 PREVENTED VC BY SUPPRESSING THE OSTEOGENIC TRANSDIFFERENTIATION OF VSMCS, AND AS SUCH TARGETING SIRT6 MAY BE AN APPEALING THERAPEUTIC TARGET FOR VC IN CKD. 2022 16 3185 23 HBC BINDS TO THE CPG ISLANDS OF HBV CCCDNA AND PROMOTES AN EPIGENETIC PERMISSIVE STATE. HBV COVALENTLY CLOSED CIRCULAR DNA (CCCDNA) IS THE TEMPLATE FOR THE TRANSCRIPTION OF HBV. HBV CORE PROTEIN (HBC) IS A MAIN COMPONENT OF THE HBV CCCDNA MINICHROMOSOME. HOWEVER, THE FUNCTION OF HBC IN CCCDNA IS NOT FULLY UNDERSTOOD. IN LIGHT OF RECENT FINDINGS THAT HBV CCCDNA MAY BE REGULATED EPIGENETICALLY, WE ANALYZED THE BINDING OF HBC TO CCCDNA AND THE IMPACT OF HBC ON CCCDNA EPIGENETIC PROFILE IN THE LIVER BIOPSY SAMPLES OF 22 PATIENTS WITH CHRONIC HEPATITIS B (CHB). WE FOUND THAT HBC BINDING TO HBV CCCDNA OCCURRED PREFERENTIALLY AT CPG ISLAND 2, AN IMPORTANT REGION FOR THE REGULATION OF HBV TRANSCRIPTION. FURTHERMORE, THE RELATIVE ABUNDANCES OF HBC BINDING TO CPG ISLAND 2 WERE POSITIVELY CORRELATED WITH THE RATIOS OF RELAXED CIRCULAR DNA TO CCCDNA AND THE LEVELS OF SERUM HBV DNA IN THOSE PATIENTS. INTERESTINGLY, THE RELATIVE ABUNDANCES OF HBC BINDING TO CPG ISLAND 2 WERE ASSOCIATED WITH THE BINDING OF CREB BINDING PROTEIN (CBP) AND WITH HYPOMETHYLATION IN CPG ISLAND 2 OF HBV CCCDNA MINICHROMOSOMES. HOWEVER, RELATIVELY HIGHER AMOUNTS OF HBC BINDING TO CPG ISLAND 2 OF CCCDNA WERE ACCOMPANIED BY LOWER AMOUNTS OF HDAC1 BINDING. MULTIVARIATE ANALYSIS REVEALED THAT THE ABUNDANCES OF HBC BINDING TO CPG ISLAND 2 OF CCCDNA AND POSITIVE HBEAG WERE INDEPENDENT FACTORS ASSOCIATED WITH THE REPLICATION OF HBV (P = 0.001 FOR BOTH). APPARENTLY, HBC IS A POSITIVE REGULATOR OF HBV TRANSCRIPTION AND REPLICATION, MAINTAINING THE PERMISSIVE EPIGENETIC STATE IN THE CRITICAL REGION OF THE HBV CCCDNA MINICHROMOSOMES. 2011 17 3246 31 HEPATITIS B VIRUS (HBV) INDUCES THE EXPRESSION OF INTERLEUKIN-8 THAT IN TURN REDUCES HBV SENSITIVITY TO INTERFERON-ALPHA. HIGH LEVELS OF SERUM INTERLEUKIN-8 (IL-8) HAVE BEEN DETECTED IN CHRONIC HEPATITIS B (CHB) PATIENTS DURING EPISODES OF HEPATITIS FLARES. WE INVESTIGATED WHETHER HEPATITIS B VIRUS (HBV) MAY DIRECTLY INDUCE IL-8 PRODUCTION AND WHETHER IL-8 MAY ANTAGONIZE INTERFERON-ALPHA (IFN-ALPHA) ANTIVIRAL ACTIVITY AGAINST HBV. WE SHOWED THAT CHB PATIENTS HAD SIGNIFICANTLY HIGHER IL-8 LEVELS BOTH IN SERUM AND IN LIVER TISSUE THAN CONTROLS. IN HBV-REPLICATING HEPG2 CELLS, IL-8 TRANSCRIPTION WAS SIGNIFICANTLY ACTIVATED. AP-1, C/EBP AND NF-KB TRANSCRIPTION FACTORS WERE CONCURRENTLY NECESSARY FOR MAXIMUM IL-8 INDUCTION. MOREOVER, HBX VIRAL PROTEIN WAS RECRUITED ONTO THE IL-8 PROMOTER AND THIS WAS PARALLELED BY IL8-BOUND HISTONE HYPERACETYLATION AND BY ACTIVE RECRUITMENT OF TRANSCRIPTIONAL COACTIVATORS. INHIBITION OF IL-8 INCREASES THE ANTIVIRAL ACTIVITY OF IFN-ALPHA AGAINST HBV. OUR RESULTS INDICATE THAT HBV ACTIVATES IL-8 GENE EXPRESSION BY TARGETING THE EPIGENETIC REGULATION OF THE IL-8 PROMOTER AND THAT IL-8 MAY CONTRIBUTE TO REDUCE HBV SENSITIVITY TO IFN-ALPHA. 2013 18 2243 36 EPIGENETIC MODULATION OF CHRONIC ANXIETY AND PAIN BY HISTONE DEACETYLATION. PROLONGED EXPOSURE OF THE CENTRAL AMYGDALA (CEA) TO ELEVATED CORTICOSTEROIDS (CORT) FACILITATES LONG-TERM ANXIETY AND PAIN THROUGH ACTIVATION OF GLUCOCORTICOID RECEPTORS (GRS) AND CORTICOTROPIN-RELEASING FACTOR (CRF). HOWEVER, THE MECHANISMS MAINTAINING THESE RESPONSES ARE UNKNOWN. SINCE CHRONIC PHENOTYPES CAN BE SUSTAINED BY EPIGENETIC MECHANISMS, INCLUDING HISTONE MODIFICATIONS SUCH AS DEACETYLATION, WE TESTED THE HYPOTHESIS THAT HISTONE DEACETYLATION CONTRIBUTES TO THE MAINTENANCE OF CHRONIC ANXIETY AND PAIN INDUCED BY PROLONGED EXPOSURE OF THE CEA TO CORT. WE FOUND THAT BILATERAL INFUSIONS OF A HISTONE DEACETYLASE INHIBITOR INTO THE CEA ATTENUATED ANXIETY-LIKE BEHAVIOR AS WELL AS SOMATIC AND VISCERAL HYPERSENSITIVITY RESULTING FROM ELEVATED CORT EXPOSURE. MOREOVER, WE DELINEATED A NOVEL PATHWAY THROUGH WHICH HISTONE DEACETYLATION COULD CONTRIBUTE TO CORT REGULATION OF GR AND SUBSEQUENT CRF EXPRESSION IN THE CEA. SPECIFICALLY, DEACETYLATION OF HISTONE 3 AT LYSINE 9 (H3K9), THROUGH THE COORDINATED ACTION OF THE NAD+-DEPENDENT PROTEIN DEACETYLASE SIRTUIN-6 (SIRT6) AND NUCLEAR FACTOR KAPPA B (NFKAPPAB), SEQUESTERS GR EXPRESSION LEADING TO DISINHIBITION OF CRF. OUR RESULTS INDICATE THAT EPIGENETIC PROGRAMMING IN THE AMYGDALA, SPECIFICALLY HISTONE MODIFICATIONS, IS IMPORTANT IN THE MAINTENANCE OF CHRONIC ANXIETY AND PAIN. 2015 19 4309 40 MICRORNAS 29B AND 181A DOWN-REGULATE THE EXPRESSION OF THE NOREPINEPHRINE TRANSPORTER AND GLUCOCORTICOID RECEPTORS IN PC12 CELLS. MICRORNAS ARE SHORT NON-CODING RNAS THAT PROVIDE GLOBAL REGULATION OF GENE EXPRESSION AT THE POST-TRANSCRIPTIONAL LEVEL. SUCH REGULATION HAS BEEN FOUND TO PLAY A ROLE IN STRESS-INDUCED EPIGENETIC RESPONSES IN THE BRAIN. THE NOREPINEPHRINE TRANSPORTER (NET) AND GLUCOCORTICOID RECEPTORS ARE CLOSELY RELATED TO THE HOMEOSTATIC INTEGRATION AND REGULATION AFTER STRESS. OUR PREVIOUS STUDIES DEMONSTRATED THAT NET MRNA AND PROTEIN LEVELS IN RATS ARE REGULATED BY CHRONIC STRESS AND BY ADMINISTRATION OF CORTICOSTERONE, WHICH IS MEDIATED THROUGH GLUCOCORTICOID RECEPTORS. WHETHER MIRNAS ARE INTERMEDIARIES IN THE REGULATION OF THESE PROTEINS REMAINS TO BE ELUCIDATED. THIS STUDY WAS UNDERTAKEN TO DETERMINE POSSIBLE REGULATORY EFFECTS OF MIRNAS ON THE EXPRESSION OF NET AND GLUCOCORTICOID RECEPTORS IN THE NORADRENERGIC NEURONAL CELL LINE. USING COMPUTATIONAL TARGET PREDICTION, WE IDENTIFIED SEVERAL CANDIDATE MIRNAS POTENTIALLY TARGETING NET AND GLUCOCORTICOID RECEPTORS. WESTERN BLOT RESULTS SHOWED THAT OVER-EXPRESSION OF MIR-181A AND MIR-29B SIGNIFICANTLY REPRESSED PROTEIN LEVELS OF NET, WHICH IS ACCOMPANIED BY A REDUCED [(3) H] NOREPINEPHRINE UPTAKE, AND GLUCOCORTICOID RECEPTORS IN PC12 CELLS. LUCIFERASE REPORTER ASSAYS VERIFIED THAT BOTH MIR-181A AND MIR-29B BIND THE 3'UTR OF MRNA OF NET AND GLUCOCORTICOID RECEPTORS. FURTHERMORE, EXPOSURE OF PC12 CELLS TO CORTICOSTERONE MARKEDLY REDUCED THE ENDOGENOUS LEVELS OF MIR-29B, WHICH WAS NOT REVERSED BY THE APPLICATION OF GLUCOCORTICOID RECEPTOR ANTAGONIST MIFEPRISTONE. THESE OBSERVATIONS INDICATE THAT MIR-181A AND MIR-29B CAN FUNCTION AS THE NEGATIVE REGULATORS OF NET AND GLUCOCORTICOID RECEPTOR TRANSLATION IN VITRO. THIS REGULATORY EFFECT MAY BE RELATED TO STRESS-INDUCED UP-REGULATION OF THE NORADRENERGIC PHENOTYPE, A PHENOMENON OBSERVED IN STRESS MODELS AND DEPRESSIVE PATIENTS. THIS STUDY DEMONSTRATED THAT MIR-29B AND MIR-181A, TWO SHORT NON-CODING RNAS THAT PROVIDE GLOBAL REGULATION OF GENE EXPRESSION, MARKEDLY REPRESSED PROTEIN LEVELS OF NOREPINEPHRINE (NE) TRANSPORTER AND GLUCOCORTICOID RECEPTOR (GR), AS WELL AS NE UPTAKE BY BINDING THE 3'UTR OF THEIR MRNAS IN PC12 CELLS. ALSO, EXPOSURE OF CELLS TO CORTICOSTERONE SIGNIFICANTLY REDUCED MIR-29B LEVELS THROUGH A GR-INDEPENDENT WAY. 2016 20 5689 29 SILENCING HEPATITIS B VIRUS COVALENTLY CLOSED CIRCULAR DNA: THE POTENTIAL OF AN EPIGENETIC THERAPY APPROACH. GLOBAL PROPHYLACTIC VACCINATION PROGRAMMES HAVE HELPED TO CURB NEW HEPATITIS B VIRUS (HBV) INFECTIONS. HOWEVER, IT IS ESTIMATED THAT NEARLY 300 MILLION PEOPLE ARE CHRONICALLY INFECTED AND HAVE A HIGH RISK OF DEVELOPING HEPATOCELLULAR CARCINOMA. AS SUCH, HBV REMAINS A SERIOUS HEALTH PRIORITY AND THE DEVELOPMENT OF NOVEL CURATIVE THERAPEUTICS IS URGENTLY NEEDED. CHRONIC HBV INFECTION HAS BEEN ATTRIBUTED TO THE PERSISTENCE OF THE COVALENTLY CLOSED CIRCULAR DNA (CCCDNA) WHICH ESTABLISHES ITSELF AS A MINICHROMOSOME IN THE NUCLEUS OF HEPATOCYTES. AS THE VIRAL TRANSCRIPTION INTERMEDIATE, THE CCCDNA IS RESPONSIBLE FOR PRODUCING NEW VIRIONS AND PERPETUATING INFECTION. HBV IS DEPENDENT ON VARIOUS HOST FACTORS FOR CCCDNA FORMATION AND THE MINICHROMOSOME IS AMENABLE TO EPIGENETIC MODIFICATIONS. TWO HBV PROTEINS, X (HBX) AND CORE (HBC) PROMOTE VIRAL REPLICATION BY MODULATING THE CCCDNA EPIGENOME AND REGULATING HOST CELL RESPONSES. THIS INCLUDES VIRAL AND HOST GENE EXPRESSION, CHROMATIN REMODELING, DNA METHYLATION, THE ANTIVIRAL IMMUNE RESPONSE, APOPTOSIS, AND UBIQUITINATION. ELIMINATION OF THE CCCDNA MINICHROMOSOME WOULD RESULT IN A STERILIZING CURE; HOWEVER, THIS MAY BE DIFFICULT TO ACHIEVE. EPIGENETIC THERAPIES COULD PERMANENTLY SILENCE THE CCCDNA MINICHROMOSOME AND PROMOTE A FUNCTIONAL CURE. THIS REVIEW EXPLORES THE CCCDNA EPIGENOME, HOW HOST AND VIRAL FACTORS INFLUENCE TRANSCRIPTION, AND THE RECENT EPIGENETIC THERAPIES AND EPIGENOME ENGINEERING APPROACHES THAT HAVE BEEN DESCRIBED. 2021